Investors

Lovaltech: Pioneering a Breakthrough in Vaccine Technology

Lovaltech is at the forefront of vaccine innovation, offering the world's first vaccine with the unique ability to halt the transmission of viruses. In addition, what sets our vaccines apart is their effectiveness against both current and emerging variants, coupled with the convenience of being storable at positive temperatures.

Key Highlights of Lovaltech:

• Robust Public Support: Secured funding exceeding 16 million euros.
• Diverse Leadership: A management team with a blend of experience and expertise.
• Expert Guidance: Guided by a scientific committee of leading experts.
• Advisory Excellence: Supported by a seasoned advisory committee.
• Technological Innovation: Our vaccines are not only highly innovative but also built on proven technologies.
• Exclusive Portfolio: We offer a range of protected products.
• Promising Future: Lovaltech is poised for significant growth and impact.

At our core, Lovaltech is a mucosal platform dedicated to inducing protective immune responses, pivotal in both immunotherapy and immunoprophylaxis across various medical indications. Our technology's unique value is its ability to create a mucosal immune shield, targeting pathogens with neutralizing specific antibodies (IgA).
Our approach has broad market applications, particularly in Oncology, Infectious Diseases, and Allergy treatments.

Flagship Innovation: Our inaugural product, a trailblazing Covid-19 vaccine under the LVT001 program, is being developed in partnership with the BioMap laboratory (affiliated with Tours University and INRAE). This pioneering vaccine is gearing up to enter phases 1 & 2 of clinical trials in 2024.

Lovaltech's Vaccines – Setting a New Standard:

1. Capability to prevent virus transmission between individuals.
2. Broad-spectrum efficacy, tailored to combat multiple strains or variants (universal application).
3. Enhanced storage and logistical ease with positive temperature stability. Furthermore, our vaccine's non-invasive nasal administration method is set to boost global vaccination rates significantly.

“Lovaltech is not just developing vaccines, we're reshaping the future of global health security."